Cargando…
From bench to bedside, 2-in-1 design expedites phase 2/3 oncology drug development
Autores principales: | Chen, Cong, Zhang, Xuekui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593414/ https://www.ncbi.nlm.nih.gov/pubmed/37876968 http://dx.doi.org/10.3389/fonc.2023.1251672 |
Ejemplares similares
-
Targeting Macrophages in Cancer: From Bench to Bedside
por: Poh, Ashleigh R., et al.
Publicado: (2018) -
Editorial: Cardio-Oncology: From Bench to Bedside
por: Abe, Jun-ichi, et al.
Publicado: (2019) -
The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside
por: Feng, Yimei, et al.
Publicado: (2021) -
Clinical Applications and Anticancer Effects of Antimicrobial Peptides: From Bench to Bedside
por: Jafari, Ameneh, et al.
Publicado: (2022) -
Editorial: Metabolic Abnormalities and Breast Cancer: Challenges From Bench to Bedside
por: Wang, Zheng, et al.
Publicado: (2022)